“It’s obvious that the overall healthcare market will continue to grow. And photonics technology – which delivers a number of unique capabilities, like non-invasive or non-contact probing at high spatial resolution – is poised to play an ever-increasing role in this field.”

Bayer boosts its gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Inc.

Bergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing.

,

Richter-Helm BioLogics has reached a further and important construction milestone during the expansion of its production site in Bovenau. We officially and ceremoniously inaugurated the new office building on May 31, 2023 together with the mayor of Bovenau, Mr. Ambrock, two years after the groundbreaking ceremony.

The Chemspec Europe 2023 provided insights into current challenges of the chemical industry, as well as the solutions it holds.

Antibodies play a vital role in the immune system by providing protection against foreign invaders, such as bacteria and viruses. Produced by B cells, antibodies are protein molecules that can be harnessed to treat cancers, autoimmune disorders, and various infectious diseases. However, the human immune system may recognize modified therapeutic antibodies as foreign substances, reducing their efficacy. To overcome this challenge, the following two processes have been developed: antibody humanization and affinity maturation.

Italian researchers have successfully ameliorated several IL-1-based autoimmune disorders by gene therapy into transplantable hematopoietic stem cells of mice.

Physiologically based pharmacokinetic (PBPK) modelling is a tool that can have a huge impact in speeding up drug development. It simulates a range of physiological factors that have an effect on how an orally dosed drug behaves, flagging up any areas where performance might be expected to be sub-optimal. This allows them to be addressed at an early stage, rather than causing bigger problems later on that might hold up development while a solution is sought.

Real Quality. Real Results. With cell & gene therapies, the process is the product – so ensuring high-quality starting material is a critical first step in maximizing your results.

Bristol-based eXmoor Pharma Ltd has completed a US$35m Series A financing to expand its cell and gene therapy manufacturing capabilities.